Novartis oncology head goes to Incyte

Share this article:

Herve Hoppenot has traded his title of president of Novartis's oncology division for president and CEO of Incyte.

Novartis posted the departure notice Sunday, and Incyte published its corporate hiring notice Monday.

Hoppenot's job changed literally overnight. Novartis said Alessandro Riva will step into Hoppenot's now-former role until the company finds a replacement, in addition to keeping abreast of his responsibilities as the global head of  Novartis oncology development and media affairs.

Hoppenot's move closes out 10 years with the Basel, Switzerland, drugmaker. PMLive notes that this tenure included launching Jakavi for myelofibrosis in 2011 and Signifor for Cushing's disease in 2012, as well as finding new indications for established drugs, including cancer meds Afinitor and Tasigna.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.